ecancermedicalscience

Conference Report

Aspirin for the next generation

2 Apr 2013
Nick Henderson, Tom Smith

First used as an analgesic and antipyretic, investigations into aspirin’s anti-inflammatory effects led to its establishment in 1974 as a drug that altered the activity of platelets to influence the course and incidence of myocardial infarction and cerebrovascular disease. It became the standard in treatment and prevention of vascular disorders.

The 25th International Scientific Meeting on aspirin held at the Royal College of Physicians in London on 24th October 2012 took aspirin into fresh fields, among them cancer, diabetes, dementia and gynaecology.

Related Articles

Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu
Fatuma Affey, Dabo Galgalo Halake, Grace Muira Wainaina, Hussein Ali Osman, James G Ndukui, Houda Abdourahman, Omar Abdihamid
Jade Tso, Mustafa Al-Qaraghli, Susana Galeas, Mustafa Faleh Abidalhassan, Cameron E Gaskill
Samuel Santiago Parra Giraldo, Rut Amparo Vergara López, Haydee De La Hoz-Herazo, Enrique Carlos Ruiz Pla, Brayan Bayona-Pacheco, Juan Jose Espitia De La Hoz
Diego Rodrigues Mendonça e Silva, Max Moura de Oliveira, Gisele Aparecida Fernandes, Maria Paula Curado